abs311.txt	background		with	total	and	out-of-pocket	spending	for	oral	oncolytics	rising	there	is	increased	interest	in	choosing	oncology	treatments	based	on	theirclinical	value	relative	to	cost	objective	determine	if	varied	higher	versus	lowerbenefit	drugs	reimbursed	by	commercial	insurers	methods	this	study	was	a	retrospective	analysis	of	insurerprescription	drug	claims	filed	between	2007	2014	13	oncolyticsapproved	before	2009	we	calculated	mean	monthly	payment	eachfill	patient	then	categorized	their	overall	andprogression-free	survival	benefits	each	fda-approved	indication	usingevidence	from	published	studies	assessed	the	relationship	benefitwith	adjusting	demographic	plancharacteristics	results	our	population	included	44	113	patients	aged	18-65	years	(mean	52	5	[sd9	4])	cancer	diagnosis	who	filled	731	354	prescriptions	most	commonlyrepresented	were	imatinib	(37	4%	fills)	lenalidomide	(17	7%	offills)	dasatinib	(10	0%	approximately	32	3%	fills	fordrug-indication	pairs	an	benefit	4+	adjustedanalyses	no	clear	pattern	suggest	that	paymentsdiffered	indication-specific	indicationsproviding	>	0	1	year	significantly	morelikely	have	lower	those	prescribed	off-label	but	significant	differences	payments	drugsand	associated	indications	any	other	category	usedoff-label	conclusions	not	clearly	relatedto	commercially	insured	findingsuggests	despite	attention	value-	indication-based	drugpricing	sharing	does	currently	reflect	these	goals	disclosures	project	supported	research	scholar	grantrsgi-14-030-01-cphps	american	society	nih	buildinginterdisciplinary	careers	women's	health	(bircwh)	k12	program	thenorth	carolina	translational	clinical	sciences	institute	(ul1tr001111)	grant	k24ca181510	national	authors	nodisclosures	data	presented	at	2017	forclinical	annual	meeting	june	chicago	illinois
